Blk suppressed LSC function through a pathway involving an upstream regulator, Pax5, and a downstream effector, p27. Inhibition of the Blk pathway accelerated CML development, whereas increased activity of the Blk pathway delayed CML development. Here, BLK is linked to chronic myelogenous leukemia, BCR-ABL1 positive.